The nature of experimental second-set kidney transplant rejection. 2. The mimicking of the haemodynamic upset by pharmacological and other means.
D000792:Angiography; D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D004285:Dogs; D004873:Ergolines / Q000494:pharmacology; D004874:Ergonovine / Q000494:pharmacology; D005260:Female; D006084:Graft Rejection; D006439:Hemodynamics; D007511:Ischemia / Q000150:complications; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D016030:Kidney Transplantation; D008954:Models, Biological; D009638:Norepinephrine / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D014043:Tolazoline / Q000494:pharmacology; D014181:Transplantation Immunology; D014182:Transplantation, Autologous; D014662:Vasoconstrictor Agents / Q000494:pharmacology*; D014667:Vasopressins / Q000494:pharmacology
D004873:Ergolines; D014662:Vasoconstrictor Agents; D010643:Phenoxybenzamine; D014667:Vasopressins; D000804:Angiotensin II; D011433:Propranolol; D014043:Tolazoline; D004874:Ergonovine; D009638:Norepinephrine